BioWorld

Oct. 29, 2007

Kosan, Roche End Partnership; Epothilone Goes Back Home

Kosan Biosciences Inc. and Roche Holding AG ended their five-year collaboration to develop and commercialize epothilones, anticancer agents that inhibit cell division. (BioWorld Today) Read More

Biotech Allozyne Improving Protein Drugs With $30M Round

Jennerex Seeks Oncolytic Strait Between Scylla And Charybdis

Clinical Data IVD Asset Sale: $19.5M For Drug, Test Bids

NovaBay Prices IPO At $4/Share Gets $20M To Advance Pipeline

Other News To Note

Clinic Roundup

Earnings Roundup

AACR Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 11, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...